Lakewood-Amedex Biotherapeutics Inc. Common Stock reports a Return on Equity (ROE) of 144.81%.

What is LABT's dividend yield?

Lakewood-Amedex Biotherapeutics Inc. Common Stock offers a dividend yield of 0.00%.

What is LABT's Quality Score?

Our AI rates LABT's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy LABT?

Our AI Timing Score for LABT is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does LABT belong to?

Lakewood-Amedex Biotherapeutics Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Lakewood-Amedex Biotherapeutics Inc. (LABT) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

LABT AI Analysis Summary

Our AI summary for LABT: Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 144.81%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 2.31

0.09 (4.05%) Day Change

Watchlist Portfolio Compare Chart

-0.61

D/E

144.8%

ROE

-2,095.8%

ROA

0.00%

Div Yield

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.31 Price 0.09 (4.05%) Day Change	NEWS SCORE: N/A

LABT, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.31
PBV / Sector	-1.37 / 44,105.10
Earning Per Share	-2.45

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	14.23 M GREAT
Average 1W Daily Value	0.38 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	N/A / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-2,095.81 / 185,260.64
ROA Average (%) / Sector	-867.10 / 36,684.64
ROA Change Average (%) / Sector	172.00 / 422,221.42 GREAT
ROE (%) / Sector	144.81 / 243,761.81 GREAT
ROE Average (%) / Sector	-256.60 / 48,758.38
ROE Change Average (%) / Sector	136.61 / 424,967.86 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:15
Symbol	LABT
Name	LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	1.75 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	3.89 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 8031 Cooper Creek Blvd., University Park, FL, United States, 34201

Phone: 941 225 2515

Website: https://lakewoodamedex.com

Sector: Healthcare >> Biotechnology

Description: Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.